Xavant Technology (Pty) Ltd announces that the US Food and Drug Administration has cleared its Stimpod NMS460 noninvasive neuromodulation device for the symptomatic relief and management of chronic intractable pain.
The device has also been cleared as an adjunctive treatment in the management of postsurgical pain, post-traumatic acute pain problems, and pain control due to rehabilitation.
The device works by applying a proprietary pulsed radio frequency waveform to the affected area transcutaneously, which then creates electromagnetic effects similar to invasive pulsed radio frequency treatments, according to a media release from the company.
The device also incorporates nerve-locating technology featuring a nerve-mapping probe that helps practitioners to locate nerves and evaluate the treatment progress of damaged nerves, the release adds.
“We are thrilled at the news that our revolutionary device can now be used in the US,” says Corlius Birkill, CEO of Xavant Technology (Pty) Ltd, in the release.
“This groundbreaking technology has the ability to help tens if not hundreds of millions of people just in the US as a valuable treatment asset for neurologists, chiropractors, acupuncturists, physical therapists, physiatrists, and medical pain practitioners.”
[Source(s): Xavant Technology (Pty) Ltd, PR Newswire]
